NO20051503L - Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme. - Google Patents

Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.

Info

Publication number
NO20051503L
NO20051503L NO20051503A NO20051503A NO20051503L NO 20051503 L NO20051503 L NO 20051503L NO 20051503 A NO20051503 A NO 20051503A NO 20051503 A NO20051503 A NO 20051503A NO 20051503 L NO20051503 L NO 20051503L
Authority
NO
Norway
Prior art keywords
pyrazolopyridines
processes
preparation
same
alk
Prior art date
Application number
NO20051503A
Other languages
English (en)
Other versions
NO20051503D0 (no
Inventor
Zhongli Zheng
Paula Ann Boriack-Sjodin
Wen-Cherng Lee
Juswinder Singh
Mary Beth Carter
Lihong Sun
Claudio Chuaqui
Paul Lyne
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO20051503D0 publication Critical patent/NO20051503D0/no
Publication of NO20051503L publication Critical patent/NO20051503L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Forbindelser med formel I har uventet høy affinitet for Alk 5 og/eller Alk 4 og kan være nyttige som antagonister derav for å forebygge og/eller behandle tallrike sykdommer, inklusive fibrotiske forstyrrelser. I en utførelsesform tilveiebringer oppfinnelsen en forbindelse med formel I:
NO20051503A 2002-09-06 2005-03-21 Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme. NO20051503L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40881102P 2002-09-06 2002-09-06
PCT/US2003/027722 WO2004022054A1 (en) 2002-09-06 2003-09-05 Pyrazolopyridines and methods of making and using the same

Publications (2)

Publication Number Publication Date
NO20051503D0 NO20051503D0 (no) 2005-03-21
NO20051503L true NO20051503L (no) 2005-03-21

Family

ID=31978684

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051503A NO20051503L (no) 2002-09-06 2005-03-21 Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.

Country Status (20)

Country Link
US (1) US7691865B2 (no)
EP (1) EP1551398A4 (no)
JP (1) JP2006502165A (no)
KR (1) KR20050057235A (no)
CN (1) CN1694698A (no)
AR (1) AR041207A1 (no)
AU (1) AU2003268447B2 (no)
BR (1) BR0314053A (no)
CA (1) CA2497970A1 (no)
EA (1) EA009441B1 (no)
GE (1) GEP20074125B (no)
IS (2) IS7725A (no)
MX (1) MXPA05002443A (no)
NO (1) NO20051503L (no)
NZ (1) NZ539069A (no)
PL (1) PL375699A1 (no)
RS (1) RS20050200A (no)
UA (1) UA80295C2 (no)
WO (1) WO2004022054A1 (no)
ZA (1) ZA200501856B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004194A1 (ja) * 2004-07-02 2006-01-12 Nishimoto, Tomo TGFβ2を標的としたアルツハイマー病治療薬のスクリーニング法
CA2584248A1 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
WO2007028051A2 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
EP1873157A1 (en) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
US8642034B2 (en) 2006-10-03 2014-02-04 Genzyme Corporation Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia
JP2010540451A (ja) * 2007-09-20 2010-12-24 ワイス・エルエルシー ピラゾロ［５，１−ｃ］［１，２，４］トリアジン、その調製法および使用法
KR20100135255A (ko) * 2008-03-14 2010-12-24 오츠카 세이야쿠 가부시키가이샤 Ｍｍｐ-2 및/또는 ｍｍｐ-9 저해제
CN101544634B (zh) * 2008-03-27 2011-08-10 天津药物研究院 2-苯基-3-取代吡唑并[1,5-a]吡啶类衍生物及其制备方法和用途
EP2402335A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402344A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
IN2014DN03049A (no) 2011-10-26 2015-05-15 Seattle Childrens Res Inst
TR201911151T4 (tr) 2013-03-14 2019-08-21 Tolero Pharmaceuticals Inc Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri.
RU2718876C2 (ru) 2013-08-23 2020-04-15 Ньюфарма, Инк. Некоторые химические соединения, композиции и способы
WO2015097121A1 (en) 2013-12-23 2015-07-02 Norgine B.V. Compounds useful as ccr9 modulators
CN106132967B (zh) * 2014-03-27 2019-05-28 詹森药业有限公司 作为ros1抑制剂的化合物
EP4006035B1 (en) * 2016-08-15 2023-11-22 Neupharma, Inc. Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer
CA3103995A1 (en) 2018-07-26 2020-01-30 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
JP2023509760A (ja) 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド Ａｌｋ５阻害剤複合体およびその使用
CN112707902B (zh) * 2020-03-23 2022-04-15 杭州阿诺生物医药科技有限公司 TGF-β受体抑制剂

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4302464A (en) 1980-10-16 1981-11-24 Pfizer Inc. Imidazolylpyridine therapeutic agents
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
JP2753659B2 (ja) * 1990-09-03 1998-05-20 株式会社大塚製薬工場 ピラゾール誘導体
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5670527A (en) 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
GB9423460D0 (en) * 1994-11-21 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US6369068B1 (en) * 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5854276A (en) 1995-06-29 1998-12-29 Fujisawa Pharmaceutical Co., Ltd. Substance WF16616, process for production thereof, and use thereof
US5837719A (en) 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5792778A (en) * 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US6083949A (en) * 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
ZA9610687B (en) 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
AU715900B2 (en) * 1996-01-11 2000-02-10 Smithkline Beecham Corporation Novel substituted imidazole compounds
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
EP0885217A4 (en) 1996-02-01 1999-04-21 Smithkline Beecham Corp ENDOTHELIN RECEPTOR ANTAGONISTS
WO1997032583A1 (en) 1996-03-08 1997-09-12 Smithkline Beecham Corporation Use of csaidtm compounds as inhibitors of angiogenesis
WO1997033883A1 (en) * 1996-03-13 1997-09-18 Smithkline Beecham Corporation Novel pyrimidine compounds useful in treating cytokine mediated diseases
US6096739A (en) 1996-03-25 2000-08-01 Smithkline Beecham Corporation Treatment for CNS injuries
US6235760B1 (en) * 1996-03-25 2001-05-22 Smithkline Beecham Corporation Treatment for CNS injuries
US5854265A (en) 1996-04-03 1998-12-29 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US6080870A (en) * 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5939557A (en) 1996-04-03 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5880140A (en) * 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5883105A (en) * 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP3418624B2 (ja) * 1996-06-10 2003-06-23 メルク エンド カンパニー インコーポレーテッド サイトカイン阻害活性を有する置換イミダゾール類
US5854264A (en) 1996-07-24 1998-12-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ATE264318T1 (de) 1996-11-19 2004-04-15 Amgen Inc Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) * 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US5939439A (en) * 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5965583A (en) 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
AU7726898A (en) * 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6087496A (en) * 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP0983260A2 (en) * 1997-05-22 2000-03-08 G.D. Searle & Co. 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
CZ9904452A3 (cs) * 1997-06-12 2002-02-13 Rhone-Poulenc Rorer Limited Cyklické acetaly imidazolylu, způsob jejich přípravy, jejich pouľití a farmaceutický prostředek, který je obsahuje
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
KR20010014288A (ko) * 1997-06-30 2001-02-26 오르토-맥네일 파마슈티칼, 인코퍼레이티드 염증성 질환의 치료에 유용한 2-치환된 이미다졸
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) * 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
AR017219A1 (es) 1997-12-19 2001-08-22 Smithkline Beecham Corp Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
EP1112070B1 (en) 1998-08-20 2004-05-12 Smithkline Beecham Corporation Novel substituted triazole compounds
DE69914357T2 (de) * 1998-11-04 2004-11-11 Smithkline Beecham Corp. Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
US6239279B1 (en) * 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
US6288089B1 (en) 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
CN1326848C (zh) * 1998-12-25 2007-07-18 帝国脏器制药株式会社 氨基吡唑衍生物
ATE241621T1 (de) * 1999-04-02 2003-06-15 Bristol Myers Squibb Pharma Co Arylsulfonyle als faktor xa inhibitoren
WO2000061576A1 (en) 1999-04-09 2000-10-19 Smithkline Beecham Corporation Triarylimidazoles
CO5170501A1 (es) * 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
JP4627944B2 (ja) 1999-06-03 2011-02-09 あすか製薬株式会社 置換ピラゾール化合物
DE60027431T2 (de) * 1999-07-02 2007-07-12 Stuart A. Rancho Santa Fe Lipton Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US20030109428A1 (en) * 1999-12-01 2003-06-12 John Bertin Novel molecules of the card-related protein family and uses thereof
DE60021423T2 (de) * 1999-12-21 2006-04-13 Sugen, Inc., San Diego 4-substituierte 7-aza-indolin-2-one und ihre verwendung als proteinkinaseinhibitoren
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
DE60103136T2 (de) 2000-03-06 2004-10-28 Smithkline Beecham Plc, Brentford Imidazolderivate als Raf-Kinase Inhibitoren
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
JP4722318B2 (ja) * 2000-06-05 2011-07-13 ローム株式会社 チップ抵抗器
GB0011092D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
JP2003535062A (ja) * 2000-06-01 2003-11-25 メルク エンド カムパニー インコーポレーテッド Ｊｎｋ阻害剤としての（二置換フェニル）ピリミジニルイミダゾール誘導体の使用
CA2409762A1 (en) 2000-06-23 2002-01-03 Donald J.P. Pinto Heteroaryl-phenyl substituted factor xa inhibitors
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
JP4105948B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
WO2002024680A1 (en) * 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Imidazole derivatives as raf kinase inhibitors
ATE297392T1 (de) 2000-10-18 2005-06-15 Ortho Mcneil Pharm Inc Substituierte imidazole, die sich für die behandlung entzündlicher krankheiten eignen
US6630325B1 (en) 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
US6603005B2 (en) 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
GB0027987D0 (en) 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
AU2002225730A1 (en) * 2000-11-16 2002-05-27 Smith Kline Beecham Corporation Compounds
EP1343779B1 (en) * 2000-11-20 2007-06-27 Smithkline Beecham Corporation Novel compounds
EP1832590B8 (en) * 2000-12-28 2012-04-25 Ono Pharmaceutical Co., Ltd. Heterotricyclic compounds as CRF receptor antagonists
US20040087623A1 (en) * 2001-02-02 2004-05-06 Gellibert Francoise Jeanne Pyrazole derivatives against tgf overexpression
WO2002062787A1 (en) * 2001-02-02 2002-08-15 Glaxo Group Limited Pyrazoles as tgf inhibitors
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
CA2445568A1 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
US6787555B2 (en) * 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6727364B2 (en) * 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
GB0127433D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
JP2005516916A (ja) * 2001-12-11 2005-06-09 スミスクライン ビーチャム コーポレーション 抗ヘルペス薬としてのピラゾロ−ピリジン誘導体
AU2003229305A1 (en) * 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
WO2004026871A1 (en) * 2002-09-17 2004-04-01 Eli Lilly And Company Novel pyrazolopyridine derivatves as pharmaceutical agents
EA200500378A1 (ru) * 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Новые соединения имидазола в качестве ингибиторов трансформирующего фактора роста (tgf)
BR0314383A (pt) * 2002-09-18 2005-07-19 Pfizer Prod Inc Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf)
US7361669B2 (en) 2003-01-02 2008-04-22 Millennium Pharmaceuticals, Inc. Compositions and method for inhibiting TGF-β
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
RU2006111093A (ru) 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атр-связывающих кассетных транспортеров

Also Published As

Publication number Publication date
WO2004022054A1 (en) 2004-03-18
BR0314053A (pt) 2005-07-19
RS20050200A (en) 2007-08-03
US7691865B2 (en) 2010-04-06
IS7725A (is) 2005-03-04
CA2497970A1 (en) 2004-03-18
AU2003268447B2 (en) 2008-07-24
KR20050057235A (ko) 2005-06-16
AR041207A1 (es) 2005-05-11
NZ539069A (en) 2007-03-30
IS7726A (is) 2005-03-04
EA200500450A1 (ru) 2005-08-25
AU2003268447A1 (en) 2004-03-29
EP1551398A4 (en) 2006-06-07
PL375699A1 (en) 2005-12-12
JP2006502165A (ja) 2006-01-19
MXPA05002443A (es) 2005-09-30
GEP20074125B (en) 2007-06-11
NO20051503D0 (no) 2005-03-21
EA009441B1 (ru) 2007-12-28
US20060106033A1 (en) 2006-05-18
EP1551398A1 (en) 2005-07-13
CN1694698A (zh) 2005-11-09
ZA200501856B (en) 2006-04-26
UA80295C2 (en) 2007-09-10

Similar Documents

Publication Publication Date Title
NO20051503L (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
NO20054200L (no) Pyrazoler samt fremgangsmate for fremstilling derav
RS95904A (en) Tri -substituted heteroaryls and methods for making and using the same
MXPA05002442A (es) Imidazolopiridinas y metodos para la elaboracion y uso de las mismas.
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
NL300933I2 (nl) Letermovir
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
TW200621752A (en) Pyrimidinylpyrazoles and methods of making and using the same
NO20062983L (no) Sulfonamid-derivater for behandling av sykdommer
WO2003028641A3 (en) Mch receptor antagonists
RS70104A (en) Nicotinamide derivatives useful as pde4 inhibitors
WO2005080324A8 (en) Sulfonamide derivatives for the treatment of diseases
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20054208L (no) Nitrogen-substituerte heksahydropyrazino[1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
NO20055219L (no) Nye forbindelser
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
NO20050828L (no) lndol-3-svovelderivater
NO20054085L (no) Substituerte heksahydropyrazino [1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter
DE60324544D1 (de) Muskarin antagonisten
TW200505865A (en) Compounds useful for the treatment of diseases
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
GB0514811D0 (en) Compounds
WO2004067703A3 (en) 5ht7 antagonists and inverse agonists
WO2004056762A3 (en) Novel aminobenzophenone compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application